Journal article
Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY
- Abstract:
-
Objective: To ascertain patient eligibility status and describe coverage of antiviral drugs and neutralising monoclonal antibodies (nMAB) as treatment for covid-19 in community settings in England.
Design: Retrospective, descriptive cohort study, approved by NHS England.
Setting: Routine clinical data from 23.4 million people linked to data on covid-19 infection and treatment, within the OpenSAFELY-TPP database.
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 1000.2KB, Terms of use)
-
- Publisher copy:
- 10.1136/bmjmed-2022-000276
Authors
- Publisher:
- BMJ
- Journal:
- BMJ Medicine More from this journal
- Volume:
- 2
- Issue:
- 1
- Article number:
- e000276
- Place of publication:
- England
- Publication date:
- 2023-01-13
- Acceptance date:
- 2022-11-25
- DOI:
- EISSN:
-
2754-0413
- Pmid:
-
36936265
- Language:
-
English
- Keywords:
- Pubs id:
-
1333367
- Local pid:
-
pubs:1333367
- Deposit date:
-
2023-12-06
Terms of use
- Copyright holder:
- Green et al
- Copyright date:
- 2023
- Rights statement:
- © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record